Jpn. J. Infect. Dis., 58 (6), 353-357, 2005
To see a printable version of the article in the Adobe file format, click this [PDF] link.
Adverse Effect of Staphylococci Slime on In Vitro Activity of Glycopeptides
Tarun Mathur, Smita Singhal, Seema Khan, Dilip Upadhyay, Tasneem Fatma1 and Ashok Rattan*
Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon 122001 and 1Department of Biosciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India
(Received May 23, 2005. Accepted September 20, 2005)
*Corresponding author: Mailing address: Department of Infectious Diseases, Ranbaxy Research Laboratories, R & D III, Plot no. 20, Sector-18, Udyog Vihar Industrial Area, Gurgaon-122001, Haryana, India. Tel: +91-124-2501-10 ext. 5223, Fax: +91-124-2343544, E-mail: email@example.com
SUMMARY: Adhesion to biomaterial is assumed to be a crucial step in the development of staphylococcal foreign body infections. Production of extracellular slime has major implications for the development and implementation of therapeutic strategies. The effect of extracted slime was investigated on the activity of vancomycin, teicoplanin, linezolid, quinupristin/dalfopristin, rifampicin and ranbezolid against 10 clinical and 4 ATCC staphylococcal isolates. The slime extract caused a 2- to 16-fold increase in the MICs of vancomycin and teicoplanin, with a shift in the MIC90 from 2 to 32 (vancomycin) and 2 to 16 (teicoplanin), whereas the MICs of linezolid and quinupristin/dalfopristin were only moderately affected. In time-kill studies, a significant decrease in bacterial killing (>3 log10 cfu/ml) was observed with vancomycin and teicoplanin (4X MIC) after addition of slime (5 and 20 mg/ml), whereas the effect of killing by linezolid and quinupristin/dalfopristin was very modest. The rifampicin and ranbezolid MICs and kill curves were not influenced by the addition of slime. The present study thus indicated that slime interferes with the antimicrobial effect of glycopeptide drugs (vancomycin, teicoplanin), and that for effective prevention and treatment of prosthetic device-related infections, appropriate and newer antibiotics such as ranbezolid should be considered.
Go to JJID Homepage
Go to JJID 58 (6) Contents